| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation to the consolidated net loss for the three and six months ended June 30, 2025 and 2024 is included at the bottom of the table below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
|
|
|
|
|
|
Revenues |
|
$ |
31,660 |
|
|
$ |
8,654 |
|
|
$ |
45,724 |
|
|
$ |
16,556 |
|
Cost of revenues |
|
|
(55 |
) |
|
|
1,407 |
|
|
|
600 |
|
|
|
2,676 |
|
Program expenses (1) |
|
|
|
|
|
|
|
|
|
|
|
|
zuranolone (ZURZUVAE) |
|
|
15,835 |
|
|
|
4,695 |
|
|
|
27,845 |
|
|
|
9,952 |
|
SAGE-319 |
|
|
2,954 |
|
|
|
2,306 |
|
|
|
4,621 |
|
|
|
3,259 |
|
SAGE-324 |
|
|
(1,597 |
) |
|
|
2,286 |
|
|
|
(2,435 |
) |
|
|
6,118 |
|
dalzanemdor |
|
|
(1,944 |
) |
|
|
15,331 |
|
|
|
(1,974 |
) |
|
|
38,999 |
|
Other research and development programs |
|
|
3,472 |
|
|
|
8,067 |
|
|
|
6,977 |
|
|
|
17,524 |
|
Non-program expenses (2) |
|
|
24,299 |
|
|
|
22,933 |
|
|
|
43,556 |
|
|
|
45,065 |
|
People and staff augmentation |
|
|
34,162 |
|
|
|
45,760 |
|
|
|
72,013 |
|
|
|
91,670 |
|
Restructuring |
|
|
(230 |
) |
|
|
— |
|
|
|
283 |
|
|
|
(597 |
) |
Other segment items (3) |
|
|
4,416 |
|
|
|
8,723 |
|
|
|
6,104 |
|
|
|
13,227 |
|
Net loss |
|
$ |
(49,652 |
) |
|
$ |
(102,854 |
) |
|
$ |
(111,866 |
) |
|
$ |
(211,337 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Includes external research and development, and selling, general and administrative expenses. |
|
(2) Includes information technology, infrastructure, facilities, legal, commercial data and systems, chemistry platform, intellectual |
|
property, and other general and administrative expense. |
|
(3) Includes stock-based compensation expense, interest income, and other (income) expense. |
|
|